SCR-1481B1

Cat. No.:	HY-18711A
CAS No.:	1174161-86-4
Molecular Formula:	$C_{28}H_{29}ClF_2N_5O_{10}P$
Molecular Weight:	699.98
Target:	c-Met/HGFR; VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (142.86 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	1.4286 mL	7.1431 mL	14.2861 mL
5 mM	0.2857 mL	1.4286 mL	2.8572 mL
10 mM	0.1429 mL	0.7143 mL	1.4286 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (3.57 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (3.57 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

SCR-1481B1 (c-Met inhibitor 2) is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.

IC_{50} & Target

VEGFR1

In Vitro

More details please refer to Patent WO 2009094417 A1.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Robert M. Borzilleri, et al. 4-pyridinone compounds and their use for cancer. WO/2009094417/A1.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA